Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

(MedPage Today) -- At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic HER2-positive breast cancer. The combination...